B-Cell Non-Hodgkin Lymphoma

hematologic malignancy

Identifier: CI-CAN-00000471
Entity page: /cancer/b-cell-non-hodgkin-lymphoma ↗
Edges: 6,945

Neighbours: 16 genes7 variants23 drugs10 trials
Drawn: 56 of 56 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
B-Cell Non-Hodgkin Lymphoma approved for …APPROVED_FOR16 of 114show all (up to 200)
← approved for	Ibritumomab Tiuxetanmonoclonal_antibody	supports	FDA ORIG	B-Cell Non-Hodgkin Lymphoma	1	Regulatory	openfda	graph →
← approved for	Denosumabmonoclonal antibody

B-Cell Non-Hodgkin Lymphoma predicts response to …PREDICTS_RESPONSE_TO7 of 7
in context · predicts response to	EZH2 A682GSNV → predicts response to Tazemetostat	sensitivity	A	B-Cell Non-Hodgkin Lymphoma	1	Curated	civic	graph →
in context · predicts response to	EZH2 A692VSNV → predicts response to Tazemetostat	sensitivity	A	B-Cell Non-Hodgkin Lymphoma	1	Curated	civic	graph →
in context · predicts response to	EZH2 Y646CSNV → predicts response to Tazemetostat	sensitivity	A	B-Cell Non-Hodgkin Lymphoma	1	Curated	civic	graph →
in context · predicts response to	EZH2 Y646HSNV → predicts response to Tazemetostat	sensitivity	A	B-Cell Non-Hodgkin Lymphoma	1	Curated	civic	graph →
in context · predicts response to	EZH2 Y646SSNV → predicts response to Tazemetostat	sensitivity	A	B-Cell Non-Hodgkin Lymphoma	1	Curated	civic	graph →
in context · predicts response to	EZH2 Y646FSNV → predicts response to Tazemetostat	sensitivity	A	B-Cell Non-Hodgkin Lymphoma	1	Curated	civic	graph →
in context · predicts response to	EZH2 Y646NSNV → predicts response to Tazemetostat	sensitivity	A	B-Cell Non-Hodgkin Lymphoma	1	Curated	civic	graph →

B-Cell Non-Hodgkin Lymphoma predicts response to …PREDICTS_RESPONSE_TO7 of 7

in context · predicts response to

EZH2 A682GSNV → predicts response to Tazemetostat

sensitivity

B-Cell Non-Hodgkin Lymphoma

Curated

B-Cell Non-Hodgkin Lymphoma altered in cohorts of …ALTERED_INderived15 of 375show all (up to 200)
← altered in cohorts of	MTRNR2L6 23 / 50 cases (46 %) · ssm · TCGA-DLBC · largest of 2 cohorts	—	—	Diffuse Large B-Cell Lymphoma	2	Observed	gdc	graph →
← altered in cohorts of	TUBB8B 23 / 50 cases (46 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	IGHV2-70 437 / 961 cases (45 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts	—	—	Multiple Myeloma	2	Observed	gdc	graph →
← altered in cohorts of	ASPM 22 / 50 cases (44 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	DSEL 22 / 50 cases (44 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	GPR149 22 / 50 cases (44 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	LAMA1 22 / 50 cases (44 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	PRSS1 22 / 50 cases (44 %) · ssm · CGCI-HTMCP-DLBCL · largest of 2 cohorts	—	—	Diffuse Large B-Cell Lymphoma	2	Observed	gdc	graph →
← altered in cohorts of	PRSS2 22 / 50 cases (44 %) · ssm · CGCI-HTMCP-DLBCL · largest of 2 cohorts	—	—	Diffuse Large B-Cell Lymphoma	2	Observed	gdc	graph →
← altered in cohorts of	ABCA13 21 / 50 cases (42 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	ADCYAP1 21 / 50 cases (42 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	AHR 21 / 50 cases (42 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	ASXL3 21 / 50 cases (42 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	CETN1 21 / 50 cases (42 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	CLUL1 21 / 50 cases (42 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →

B-Cell Non-Hodgkin Lymphoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 267show all (up to 200)
→ investigated in trials for	Dexamethasonesmall molecule 781 trials (243 active) · roll-up of the cancer and its descendants	—	—	B-Cell Non-Hodgkin Lymphoma	781	Observed	clinicaltrials	graph →
→ investigated in trials for	Rituximabmonoclonal antibody 608 trials (211 active) · roll-up of the cancer and its descendants	—	—	B-Cell Non-Hodgkin Lymphoma	608	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenalidomidesmall molecule 568 trials (207 active) · roll-up of the cancer and its descendants	—	—	B-Cell Non-Hodgkin Lymphoma	568	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 512 trials (167 active) · roll-up of the cancer and its descendants	—	—	B-Cell Non-Hodgkin Lymphoma	512	Observed	clinicaltrials	graph →
→ investigated in trials for	Bortezomibsmall molecule 456 trials (99 active) · roll-up of the cancer and its descendants	—	—	B-Cell Non-Hodgkin Lymphoma	456	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 267 trials (69 active) · roll-up of the cancer and its descendants	—	—	B-Cell Non-Hodgkin Lymphoma	267	Observed	clinicaltrials	graph →
→ investigated in trials for	Daratumumabmonoclonal antibody 223 trials (120 active) · roll-up of the cancer and its descendants	—	—	B-Cell Non-Hodgkin Lymphoma	223	Observed	clinicaltrials	graph →
→ investigated in trials for	Melphalansmall molecule 210 trials (27 active) · roll-up of the cancer and its descendants	—	—	B-Cell Non-Hodgkin Lymphoma	210	Observed	clinicaltrials	graph →
→ investigated in trials for	Pomalidomidesmall molecule 203 trials (87 active) · roll-up of the cancer and its descendants	—	—	B-Cell Non-Hodgkin Lymphoma	203	Observed	clinicaltrials	graph →
→ investigated in trials for	Prednisonesmall molecule 179 trials (71 active) · roll-up of the cancer and its descendants	—	—	B-Cell Non-Hodgkin Lymphoma	179	Observed	clinicaltrials	graph →
→ investigated in trials for	Carfilzomibother 174 trials (68 active) · roll-up of the cancer and its descendants	—	—	B-Cell Non-Hodgkin Lymphoma	174	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 167 trials (71 active) · roll-up of the cancer and its descendants	—	—	B-Cell Non-Hodgkin Lymphoma	167	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall molecule 166 trials (64 active) · roll-up of the cancer and its descendants	—	—	B-Cell Non-Hodgkin Lymphoma	166	Observed	clinicaltrials	graph →
→ investigated in trials for	Ibrutinibsmall molecule 165 trials (58 active) · roll-up of the cancer and its descendants	—	—	B-Cell Non-Hodgkin Lymphoma	165	Observed	clinicaltrials	graph →
→ investigated in trials for	Venetoclaxsmall molecule 144 trials (81 active) · roll-up of the cancer and its descendants	—	—	B-Cell Non-Hodgkin Lymphoma	144	Observed	clinicaltrials	graph →

B-Cell Non-Hodgkin Lymphoma studied in …STUDIED_INderived10 of 6,180show all (up to 200)
→ studied in	NCT00423644Phase 2 · completed A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b · condition mapped CURATED_EXACT · 6,180 trials mapped (2,051 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01559935Phase 2 · completed Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma · condition mapped CURATED_EXACT · 6,180 trials mapped (2,051 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped CURATED_EXACT · 6,180 trials mapped (2,051 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 6,180 trials mapped (2,051 active)	—	—	ALK-Positive Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05228470Phase 2 · completed A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. · condition mapped ALIAS · 6,180 trials mapped (2,051 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05354557Phase 2 · active not recruiting Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) · condition mapped CURATED_EXACT · 6,180 trials mapped (2,051 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05952024Phase 2 · recruiting Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL · condition mapped CURATED_BROADER · 6,180 trials mapped (2,051 active)	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06055075Phase 1/Phase 2 · terminated A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 6,180 trials mapped (2,051 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06179888Phase 2 · suspended Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma · condition mapped CURATED_EXACT · 6,180 trials mapped (2,051 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06337318Phase 3 · recruiting Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 6,180 trials mapped (2,051 active)	—	—	Classic Follicular Lymphoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains